Branded Xyzal, an allergy treatment, has $200 million in annual US sales.
Perrigo Company (Nasdaq:PRGO; TASE:PRGO) has bought the exclusive US marketing rights to generic Xyzal from Synthon Pharmaceuticals Inc. Xyzal is an allergy treatment made by UCB Inc. (Euronext: UCB)
Xyzal and UCB are in litigation over the ANDA filing with the US Food and Drug Administration (FDA) over generic Synthon. Brand Xyzal has $200 million in annual US sales, and has 15% annual growth, according to Wolters, Kluwer.
Perrigo rose 1.7% in early trading on Nasdaq today to $35.30, and rose 1% on the TASE.
Published by Globes [online], Israel business news - www.globes-online.com - on September 8, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008